Drugs / Anti-CD38 antibody
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06168851 | Dec 2023 → Dec 2025 overdue | autoimmune thrombocytopenia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT06014775 | Dec 2023 → Aug 2025 overdue | Evans syndrome | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Anti-CD38 antibody | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06014775 ↗ |
| Action | Deplete | “the use of CD38 monoclonal antibody to clear long-term surviving plasma cells in ITP patients may be a new strategy for treating ITP patients.” NCT06168851 ↗ |
| Modality | Monoclonal antibody | “Anti-CD38 antibody is a new type of monoclonal antibody targeting CD38.” NCT06168851 ↗ |
| Route | Intravenous | “intravenous Anti-CD38 antibody administration” NCT06014775 ↗ |
| Target | CD38 | “Anti-CD38 antibody administration” NCT06014775 ↗ |